We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

N-acetylcysteine in Bulimia Nervosa

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01131572
First Posted: May 27, 2010
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lindner Center of HOPE
  Purpose
This study tests NAC in the treatment of Bulimia Nervosa.

Condition Intervention Phase
NAC Drug: N-acetylcysteine NAC Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Lindner Center of HOPE:

Primary Outcome Measures:
  • Binge-purge episodes [ Time Frame: per week ]
    The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.


Enrollment: 11
Study Start Date: February 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
N-acetylcysteine
open label treatment. Each subject receives N-acetylcysteine.
Drug: N-acetylcysteine NAC
N-acetylcysteine in the treatment of Bulimia Nervosa

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Bulimia Nervosa
  • 18-65 years of age
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131572


Locations
United States, Ohio
Lindner Center of HOPE
Mason, Ohio, United States, 45040
Sponsors and Collaborators
Lindner Center of HOPE
  More Information

Additional Information:
Publications:
Responsible Party: Lindner Center of HOPE
ClinicalTrials.gov Identifier: NCT01131572     History of Changes
Other Study ID Numbers: IRB19223, 09-09-18-01
First Submitted: May 24, 2010
First Posted: May 27, 2010
Last Update Posted: October 12, 2017
Last Verified: May 2013

Additional relevant MeSH terms:
Acetylcysteine
N-monoacetylcystine
Antiviral Agents
Anti-Infective Agents
Expectorants
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antidotes